Snappy newsletters. Simple Facebook sharing. Spirited comments. Sweet features are waiting… GET THEM NOW!

Cheap Anticancer Drugs Are Ignored

Why? They don't make pharmeceutical companies enough money

By NewsDude ,  Newser Staff

Posted Apr 5, 2007 9:51 PM CDT

(Newser) – Ralph Moss writes about why inexpensive cancer treatments get no research dollars. The publisher of a newsletter that covers both conventional and alternative cancer therapies, Moss blames the inability to patent already discovered and available chemicals and drugs for the situation.

Researchers exploring several promising substances, including 3-bromopyruvate, dichloroacetate, and melatonin ($6.99 for 60 pills at Walgreen's) cannot get funding.  Moss urges the expansion of the FDA's "orphan drug" program, which subsidizes unprofitable drugs, to cover low-cost anticancer drugs. And he concludes, "We need to foster a research and development environment in which anticancer activity is the main criterion for new drug development." 

Johns Hopkins Hospital Continues Cancer Research And Treatment
Johns Hopkins Hospital Continues Cancer Research And Treatment   (Getty Images)
« Prev« Prev | Next »Next » Slideshow
To report an error on this story, notify our editors.
A snapshot of the day's best news stories.
 
COMMENTS
Be the first to comment on this story.

More Newser Stories

Bloodthinner Can Help Frostbite Victims

New Drug Battles Liver Cancer

Scientists ID New Breast Cancer Genes

Britain OKs Human-Animal Hybrids for Research

Bacteria Battle Depression


NEWS FROM OUR PARTNERS
Other Sites We Like:   24/7 Wall St.   |   Betty Confidential   |   BuzzFeed   |   Cracked   |   Fark   |   Timelines   |   The Frisky   |   Geek Sugar   |   NewsOne